Evidence map›Paper›PMID 38796481›Full record

SynthesisScientific reports2024

Systematic review and meta-analysis: proton pump inhibitors slightly decrease the severity of chronic cough.

Diana-Elena Floria, Mahmoud Obeidat, Sarolta Beáta Kávási, Brigitta Teutsch, Dániel Sándor Veres, Krisztina Hagymási, Péter Hegyi, Vasile-Liviu Drug, Bálint Erőss

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Diana-Elena FloriaCentre for Translational Medicine, Semmelweis University, Üllői Út 26, Budapest, 1085, Hungary.
Mahmoud ObeidatCentre for Translational Medicine, Semmelweis University, Üllői Út 26, Budapest, 1085, Hungary.
Sarolta Beáta KávásiCentre for Translational Medicine, Semmelweis University, Üllői Út 26, Budapest, 1085, Hungary.
Brigitta TeutschCentre for Translational Medicine, Semmelweis University, Üllői Út 26, Budapest, 1085, Hungary.
Dániel Sándor VeresCentre for Translational Medicine, Semmelweis University, Üllői Út 26, Budapest, 1085, Hungary.
Krisztina HagymásiCentre for Translational Medicine, Semmelweis University, Üllői Út 26, Budapest, 1085, Hungary.
Péter HegyiCentre for Translational Medicine, Semmelweis University, Üllői Út 26, Budapest, 1085, Hungary.
Vasile-Liviu DrugGrigore T. Popa University of Medicine and Pharmacy Iaşi, University Street 16, Iaşi, 700115, Romania.
Bálint ErőssCentre for Translational Medicine, Semmelweis University, Üllői Út 26, Budapest, 1085, Hungary. dr.eross.balint@gmail.com.

Funding

ÚNKP-22-3 New National Excellence Program of the Ministry for Innovation and Technology ÚNKP-22-3-I-PTE-1693
6 · The paper itself

Abstract

The Montreal consensus recognizes chronic cough as an extra-esophageal manifestation of gastroesophageal reflux disease. We performed a meta-analysis to assess the effects of acid-suppressive medications in adults with non-specific chronic cough. The protocol was registered on PROSPERO (CRD42022368769). Placebo-controlled randomized trials evaluating the impact of acid-suppressive medications on persistent cough were included. The systematic search was performed on the 1st of November 2022 in three databases. A random-effects model was used for the calculations. The effect size was the standardized mean difference (SMD) with 95% confidence interval (CI). A total number of 11 double-blinded placebo-controlled randomized trials were included in the meta-analysis. Data showed that compared to placebo, PPIs decreased the severity of cough (SMD 0.33; CI 0.05; 0.61). Therapeutic response was not different in patients with non-specific chronic cough only, compared to those with laryngopharyngeal reflux. Prolonged treatment durations did not result in greater symptomatic improvement, with SMD 0.33 (CI - 0.22; 0.88), 0.31 (CI - 1.74; 2.35), 0.32 (CI - 0.29; 0.93) and 0.34 (CI - 0.16; 0.85), following 4, 6, 8 and 12 weeks of treatment, respectively. The pooled analysis of the improvement in quality of life with PPIs found an SMD of 0.39 (CI - 0.51; 1.29). PPIs mildly decrease the severity of non-specific chronic cough, irrespective of treatment duration.

Indexed as

Chronic CoughProton Pump InhibitorsChronic DiseaseGastroesophageal RefluxHumansRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeProton Pump Inhibitors

Identifiers

PMID38796481
PMCPMC11127940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.